HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Michel Boussinesq Selected Research

Pharmaceutical Preparations

1/2022Adverse reactions with levamisole vary according to its indications and misuse: A systematic pharmacovigilance study.
1/2021Serious adverse reactions associated with ivermectin: A systematic pharmacovigilance study in sub-Saharan Africa and in the rest of the World.
6/2020Community-based door to door census of suspected people living with epilepsy: empowering community drug distributors to improve the provision of care to rural communities in Cameroon.
1/2020Effects of an injectable long-acting formulation of ivermectin on Onchocerca ochengi in zebu cattle.
4/2019Risk factors for lymphatic filariasis in two villages of the Democratic Republic of the Congo.
4/2019Effect of a Single Standard Dose (150-200 μg/kg) of Ivermectin on Loa loa Microfilaremia: Systematic Review and Meta-analysis.
10/2018A new powerful drug to combat river blindness.
9/2013Impact of repeated ivermectin treatments against onchocerciasis on the transmission of loiasis: an entomologic evaluation in central Cameroon.
1/2013Dynamics of Onchocerca volvulus microfilarial densities after ivermectin treatment in an ivermectin-naïve and a multiply treated population from Cameroon.
7/2010Analysis of the mdr-1 gene in patients co-infected with Onchocerca volvulus and Loa loa who experienced a post-ivermectin serious adverse event.
For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Michel Boussinesq Research Topics

Disease

48Onchocerciasis
10/2021 - 07/2002
23Infections
12/2021 - 03/2002
16Filarial Elephantiasis (Lymphatic Filariasis)
12/2021 - 06/2004
12Intestinal Volvulus (Volvulus)
01/2021 - 07/2002
8Loiasis
01/2022 - 05/2011
5Brain Diseases (Brain Disorder)
01/2022 - 10/2003
4Coinfection
01/2021 - 02/2014
4Epilepsy (Aura)
01/2021 - 12/2018
4Ocular Onchocerciasis (River Blindness)
10/2018 - 09/2009
3Filariasis
01/2021 - 11/2013
3Helminthiasis (Helminthiases)
06/2020 - 12/2003
3Trichuriasis
01/2020 - 02/2002
2Neglected Diseases
01/2022 - 01/2020
2Neoplasms (Cancer)
01/2022 - 12/2012
2Drug-Related Side Effects and Adverse Reactions
01/2022 - 01/2021
2Malaria
06/2020 - 01/2020
2Coma (Comas)
07/2010 - 04/2008
2Nematode Infections
04/2008 - 06/2005
2Pruritus (Itching)
01/2006 - 07/2002
1Mental Disorders (Mental Disorder)
01/2022
1Digestive System Diseases
01/2022
1Vasculitis (Vasculitides)
01/2022
1Hemorrhage
01/2021
1Scabies (Sarcoptic Mange)
01/2020
1Communicable Diseases (Infectious Diseases)
12/2012
1Hypertension (High Blood Pressure)
12/2012
1Peripheral Nervous System Diseases (PNS Diseases)
05/2011
1Sleep Initiation and Maintenance Disorders (Insomnia)
01/2006
1Reinfection
11/2004
1Persistent Infection
03/2002
1Necrosis
02/2002

Drug/Important Bio-Agent (IBA)

51Ivermectin (Mectizan)FDA Link
11/2021 - 07/2002
14Pharmaceutical PreparationsIBA
01/2022 - 08/2004
8Albendazole (Albenza)FDA Link
12/2021 - 05/2011
7AntigensIBA
01/2021 - 02/2002
5CytokinesIBA
04/2008 - 03/2002
4Apolipoproteins C (ApoC)IBA
06/2016 - 08/2004
3Levamisole (Decaris)FDA Link
01/2022 - 04/2019
3Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA
11/2004 - 02/2002
2Ribosomal DNA (rDNA)IBA
01/2021 - 06/2020
2DNA (Deoxyribonucleic Acid)IBA
01/2021 - 06/2020
2Diethylcarbamazine (Hetrazan)FDA Link
01/2020 - 01/2007
2Antiparasitic Agents (Antiparasitics)IBA
01/2016 - 05/2008
2TubulinIBA
09/2012 - 08/2007
2Interferon-gamma (Interferon, gamma)IBA
04/2008 - 11/2004
2Interleukin-10 (Interleukin 10)IBA
04/2008 - 02/2002
2Immunoglobulin E (IgE)IBA
06/2005 - 03/2002
2Immunoglobulin G (IgG)IBA
06/2005 - 03/2002
2InterleukinsIBA
11/2004 - 02/2002
2Interleukin-13IBA
11/2004 - 02/2002
1Fluorouracil (Carac)FDA LinkGeneric
01/2022
1Complement System Proteins (Complement)IBA
10/2021
1benzimidazoleIBA
01/2021
1Immunoglobulins (Immunoglobulin)IBA
01/2021
1AntibodiesIBA
01/2021
1TabletsIBA
06/2020
1Vitamin A (Retinol)FDA LinkGeneric
06/2020
1AnthelminticsIBA
01/2020
1Trinitrotoluene (TNT)IBA
01/2018
1Doxycycline (Periostat)FDA LinkGeneric
01/2018
1ImmunosorbentsIBA
01/2016
1EnzymesIBA
01/2016
1Tobacco Smoke Pollution (Passive Smoking)IBA
12/2012
1MicronutrientsIBA
12/2012
1Vascular Endothelial Growth Factor CIBA
12/2009
1Angiopoietin-1IBA
12/2009
1Angiopoietin-2IBA
12/2009
1MitogensIBA
04/2008
1Transforming Growth Factor beta1 (TGF beta 1)IBA
04/2008
1Bacterial AntigensIBA
04/2008
1Helminth AntigensIBA
04/2008
1Member 1 Subfamily B ATP Binding Cassette TransporterIBA
04/2008
1ATP-Binding Cassette Transporters (ABC Transporters)IBA
04/2008
1Proteins (Proteins, Gene)FDA Link
04/2008
1AllergensIBA
06/2005
1Interleukin-5 (Interleukin 5)IBA
11/2004
1Anticonvulsants (Antiepileptic Drugs)IBA
07/2003
1Immunoglobulin A (IgA)IBA
03/2002

Therapy/Procedure

17Mass Drug Administration
06/2021 - 05/2015
4Aftercare (After-Treatment)
10/2020 - 04/2008
1Drug Therapy (Chemotherapy)
01/2022
1Insecticide-Treated Bednets
06/2020
1Contraindications
01/2018
1Ambulatory Care (Outpatient Care)
12/2012